FORMULARY WATCH

Biosimilars

Biosmilars' naming proposal could cause "significant" changes

By Christine Blank
Pharmacies should be wary of potential drug name changes that could occur if FDA finalizes its new draft guidance on biosimilar naming, which proposes proper names for biosimilars. The changes

Sandoz touts value of first biosimilar for cancer

By Christine Blank
The first biosimilar drug approved by FDA in March was officially launched in the United States on September 3 – at a value compared to competing medications. Read more

CONTINUING EDUCATION

Primer on inhalers and nebulizers

This month's CE activity is part of the CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss the various types of inhaled devices and educate pharmacists on the techniques for correct device use.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT33-FTX29.

The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php.
All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce

[BLOG]: 5 reasons biosimilars must have distinguishable names

By Louis Tharp
There are 5 simple reasons why biosimilars must be given distinguishable names and made available only under transparent circumstances. Get the info

September 9, 2015